Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval

Simply Wall St.07-11

Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650513068?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-11 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650513068","market":"nz","top_or_hot":-1,"title":"Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval","media":"Simply Wall St.","content":"<div>\n<p>Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-11 04:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte","article_id":"2650513068","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650513068","pubTimestamp":1783716161,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new chapter for the stock.\nSee our latest analysis for Viridian Therapeutics.\nThe FDA approval has put Viridian Therapeutics back on traders’ radar, with a 30 day share price return of 23.85% and a 90 day share price return of 35.12%. However, the year to date share price return is still down 34.16%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","VRDN":"Viridian Therapeutics, Inc.","LABU":"三倍做多标普生物-Direxion"},"translate_title":"FDA 批准后 Viridian Therapeutics (VRDN) 可能比公允价值低 87%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"LABU":1.5,"VRDN":1.5},"content_text":"Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new chapter for the stock. See our latest analysis for Viridian Therapeutics. The FDA approval has put Viridian Therapeutics back on traders’ radar, with a 30 day share price return of 23.85% and a 90 day share price return of 35.12%. However, the year to date share price return is still down 34.16%, while the 1 year total shareholder return of 17.92% points to improving sentiment over a longer window. If Lumvoa has you looking more closely at healthcare and biotech, this could be a good moment to scan for other opportunities in similar areas through the 40 healthcare AI stocks Viridian Therapeutics now has an approved drug, rising revenue, and a larger pipeline in motion, but the stock’s sharp recent rebound still sits against a weak year to date performance. How do those pieces compare with today’s valuation? AdvertisementPreferred Price-to-Sales Multiple of 31.5x: Is it justified? Viridian Therapeutics now trades with a P/S ratio of 31.5x, alongside a last close of $20.20 and a recent shift in sentiment after Lumvoa’s approval. The P/S ratio compares the company’s market value to its revenue. This can be especially relevant for a business like Viridian Therapeutics that is still reporting losses but has an approved product and a developing pipeline. Against that backdrop, Viridian Therapeutics screens as expensive on several fronts. Its 31.5x P/S ratio is above the US Biotechs industry average of 12.4x, above the peer average of 18.4x, and far above an estimated fair P/S ratio of 0.1x that our model suggests the market could shift toward if expectations reset. Explore the SWS fair ratio for Viridian Therapeutics Result: Price-to-Sales of 31.5x (OVERVALUED) However, Viridian Therapeutics still reports a net loss of $303.267 million and trades at a high P/S multiple, so pipeline or commercial setbacks could quickly pressure sentiment. Find out about the key risks to this Viridian Therapeutics narrative. Another view on Viridian Therapeutics: what the DCF model suggests The earlier P/S check painted Viridian Therapeutics as expensive, but the SWS DCF model points in the opposite direction. At a share price of $20.20, the stock is described as trading about 87.2% below an estimated future cash flow value of $157.80, implying a very different story about upside and risk. That kind of gap between the market price and an internally estimated fair value raises a practical question for investors: which signal deserves more weight, the rich sales multiple or the discounted cash flow view? Look into how the SWS DCF model arrives at its fair value. VRDN Discounted Cash Flow as at Jul 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If the mixed signals around Viridian Therapeutics have you on the fence, take a closer look at the data now and form your own view with the 2 key rewards and 2 important warning signs Looking for more investment ideas beyond Viridian Therapeutics? If Viridian Therapeutics has sharpened your focus, do not stop here. Use these targeted stock ideas to broaden your watchlist and stay aware of potential opportunities.  Look for potential mispricing by scanning for companies that combine quality fundamentals with specific valuation characteristics through the 44 high quality undervalued stocks. Review companies with higher yields and particular payout profiles using the 9 dividend fortresses. Focus on companies with specific financial characteristics through the 73 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650513068","isCrawlerRequest":true}